Trial Profile
A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Dasotraline (Primary)
- Indications Binge-eating disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 08 Sep 2020 Results assessing the efficacy and safety of dasotraline in adults with binge-eating disorder published in the Journal of Clinical Psychiatry
- 23 May 2017 Results published in the Sunovion Pharmaceuticals Media Release
- 13 Jan 2017 According to a Sunovion Pharmaceuticals Media Release, full results of study SEP360-221 and study SEP360-301 are being analyzed and will be presented at upcoming scientific meetings.